Endoron Medical

Key People

• Ronit Harpaz - Co-Founder & Chief Executive Officer
  Email: [emailprotected]
• Eyal Teichman - Co-Founder & Chief Technology Officer
• Prof. Ron Karmeli - Co-Founder & Chief Medical Officer
• Prof. Jacques Sguin - Chairman of the Board

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful track records in MedTech.

Endoron's leadership includes individuals like Prof. Jacques Sguin, known for developing the CoreValve TAVR system, and Ronit Harpaz, former CEO of Bendit Technologies. Their combined expertise in MedTech innovation and commercialization enhances the company's prospects.

Clinical Need

Aspect: Very Strong
Summary: Aortoseal addresses significant challenges in endovascular aneurysm repair (EVAR).

Aortoseal is designed to improve the sealing and fixation of endografts in EVAR, particularly for complex aortic anatomies. This innovation aims to reduce complications like endoleaks and graft migration, addressing a substantial unmet need in vascular surgery.

Competition

Aspect: Somewhat crowded
Summary: The EVAR market has multiple players, but Aortoseal offers a unique solution.

The EVAR market includes established companies offering various endograft solutions. However, Aortoseal's catheter-based EndoStapling technology provides a novel method for enhancing graft fixation and sealing, potentially setting it apart from existing products.

Technical Challenge

Aspect: Moderate
Summary: Developing a reliable endostapling device presents moderate technical challenges.

Creating a device that can effectively and safely staple endografts within the vascular system involves overcoming challenges related to device delivery, deployment precision, and long-term durability. These are manageable but require thorough engineering and testing.

Patent

Aspect: Strong
Summary: Endoron holds multiple patents for its Aortoseal technology.

Endoron has secured patents covering various aspects of its Aortoseal device, including its unique stapling mechanism and delivery system. This strong IP position helps protect the technology from competitors and adds value to the company.

Financing

Aspect: Well-funded
Summary: Endoron has secured significant funding to support its development.

With a $10 million Series A funding round led by Sofinnova Partners and a 2.5 million grant from the European Commission's EIC Accelerator program, Endoron has the necessary resources to advance Aortoseal through clinical validation and towards commercialization.

Regulatory

Aspect: Running FIH
Summary: Aortoseal is progressing through early feasibility studies under IDE approval.

Endoron has received Investigational Device Exemption (IDE) approval from the FDA to conduct Early Feasibility Studies (EFS) for Aortoseal. This indicates progress in the regulatory pathway, moving towards eventual market approval.

Opportunity Rollup

Odds of Success

3.9

Peak Market Share

4.8

Segment CAGR

5.1%

Market Segment

Cardiovascular Devices

Market Sub Segment

Aortic and Vascular Graft Devices

Key Takeaway

Endoron Medical's Aortoseal presents a promising solution to enhance EVAR outcomes, supported by a strong team and substantial funding, positioning it well in a growing market segment.